When cells divide, they face a perilous task: unzipping billions of DNA building blocks and copying them perfectly, even when damage gets in the way. Researchers at The University of Texas Medical Branch have just discovered how one crucial enzyme acts as a guardian during this vulnerable moment—findings that could reshape the future of cancer treatment.
Each time a cell replicates, it must duplicate the entire spiral of genetic material that makes up chromosomes, copying the letters A, T, C, and G in precise order. Everyday hazards like sunlight and normal cellular metabolism damage these building blocks along the way. When the cell's copying machinery, called the replisome, encounters this damage, the replication process stalls—and here's where the trouble begins. Without intervention, the machinery can fall apart entirely, leaving chromosomes broken and unstable.
The enzyme ATR, Jung-Hoon Yoon and Karthi Sellamuthu discovered while working in the laboratories of Satya Prakash and Louise Prakash, acts as a stabilizing force at these dangerous moments. ATR holds the replication machinery firmly in place at the damaged site long enough for another enzyme to perform a rescue operation called translesion synthesis. During this process, a specialized polymerase carefully copies past the lesion while the rest of the machinery remains anchored. Without ATR doing its job, this coordination collapses—the DNA continues to unzip, copying proteins drop away, and chromosomes break.
The numbers reveal how critical this protection is. In cells where ATR was switched off, ultraviolet light exposure caused chromosome breaks to increase roughly tenfold. About one in ten chromosomes showed visible damage. When ATR functioned normally, the rate dropped to roughly one in one hundred—a tenfold improvement. The research team, working with cultured human and mouse cells, tracked exactly what happens protein by protein at these stalled replication sites, revealing the molecular choreography that protects us from chromosome instability—the very thing that causes cancer.
But the discovery carries an unexpected twist with implications for how we develop cancer drugs. ATR is already a target of experimental cancer medications, based on sound logic: cancer cells divide rapidly and depend heavily on ATR to survive. The new research, published in Genes & Development, suggests that blocking ATR may pose greater risks to healthy tissue than previously understood. In normal human cells, the DNA copying process has evolved to be nearly error-free, protecting chromosome stability. In cancer cells, that same process is far sloppier and runs detached from the replisome—which actually destabilizes them further.
"In normal human cells, the process for copying past the DNA damage has been tuned to be almost error-free, and it protects chromosomes from instability," Satya Prakash explained. This distinction matters because blocking ATR in healthy people could increase chromosome breaks, heighten sensitivity to chemotherapies like cisplatin, and over time raise the risk of new cancers caused by the treatment itself. The damage would likely appear first in tissues that divide most rapidly—the gut lining and bone marrow.
The encouraging news is that drug developers are already working to design ATR inhibitors that more precisely target cancer cells while sparing healthy tissue. This research provides the scientific foundation for that more nuanced approach, offering a path toward cancer treatments that protect patients from the very complications they're meant to prevent.